B. Bolemon

发表

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).

A. Ross, N. Vogelzang, N. Gabrail, 2021 .

Optimal Timing of Systemic Therapy in Resectable Colorectal Liver Metastases

E. Levine, P. Shen, C. Ihemelandu, 2013, The American surgeon.